{
  "docId": "019de076-c164-739c-925e-e97b24983f20",
  "docSlug": "45699c5d62cd10656fd74cee2718d284",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 45,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "key_messages",
  "function": "quantify_opportunity",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a comparison layout to contrast two distinct drug development programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-c164-739c-925e-e97b24983f20/26",
  "deckHref": "/decks/019de076-c164-739c-925e-e97b24983f20",
  "deckJsonHref": "/decks/019de076-c164-739c-925e-e97b24983f20.json",
  "deckAnchorHref": "/decks/019de076-c164-739c-925e-e97b24983f20#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.15,
        "y": 0.81
      },
      "kind": "callout",
      "text": "First-in-class TTR depleter with potential to reverse the course of disease",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e34a3873-c2d4-4e18-b876-ee6ee4a2ca4c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.55,
        "y": 0.81
      },
      "kind": "callout",
      "text": "3x Strensiq addressable population",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec686c7a-03cc-4db6-b0b4-3a4560dd5ece",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.35,
        "x": 0.58,
        "y": 0.38
      },
      "kind": "chart",
      "text": "efzimfotase alfa patient population breakdown",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33ddb317-b5a9-43d7-b15f-86c8214b2ba3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.65,
        "y": 0.265
      },
      "kind": "paragraph",
      "text": "efzimfotase alfa (ALXN1850) Next-gen enzyme replacement therapy | HPP",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d1f0d46-f392-460e-a1d1-fbeb29fb3fc8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.25,
        "y": 0.265
      },
      "kind": "paragraph",
      "text": "ALXN2220 Novel TTR depleter | ATTR-CM",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ca8185b-89cc-4406-a1bf-5dc5cc4e9bb6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Increase in addressable population driven by expanded indication of efzimfotase alfa (ALXN1850) to include patients with adult-onset HPP (vs. paediatric-onset HPP only with Strensiq (ex-JP) and removal of regional restrictions for patients with bone manifestations.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b72124f3-d771-46da-a064-7baba62bae82",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "New Phase III trial starts with blockbuster potential",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9642650-0fc2-4364-b376-8d6b191c89e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Rare Disease – R&D",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a6ce484-85f6-4cac-bb8a-f3aa732461ac",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "348bd385-bbca-48a6-95ad-d7be1022b55b",
      "evidence": "Rare Disease – R&D",
      "confidence": 0.7
    },
    {
      "name": "Call to action",
      "slug": "call-to-action",
      "agent": null,
      "layer": "slide",
      "matchId": "bdba9527-ed73-42ca-9b88-ab75ffc0beb7",
      "evidence": "New Phase III trial starts with blockbuster potential",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "dd78268a-f598-48fe-b258-b592f8aedd70",
      "evidence": "Side-by-side presentation of two distinct drug programs",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 26,
      "from": 10,
      "beatId": "43aa94ba-8d07-4798-99cd-6d40ae4b13e2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document provides an overview of AstraZeneca's financial results and pipeline success",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}